

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/730,751	12/08/2003	Stavros C. Manolagas	3650.1003-007	4492
7590 09/12/2007 McTavish Patent Firm		EXAMINER		
429 Birchwood Courts			SHAFER, SHULAMITH H	
Birchwood, MN 55110			ART UNIT	PAPER NUMBER
			1647	
•				
			MAIL DATE	DELIVERY MODE
	•		09/12/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10730751	12/8/2003	MANOLAGAS ET AL.	3650.1003-007

MANOLAGAS ET AL. 3650.1003-007

McTavish Patent Firm 429 Birchwood Courts

Birchwood, MN 55110

EXAMINER

Shulamith H., Shafer, Ph.D.

ART UNIT PAPER 20070907 1647

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The amendment to the claims, submitted on 25 June 2007, is non-responsive. The claims have been amended so that they no longer read on the elected invention. In response to restriction requirement of 8 July 2005, applicants elected, without traverse, Group II drawn to methods of screening for compounds that increase bone mineral density (election made 12 December 2005) and in response to requirement for species election, elected without traverse, in vitro screening (election made 6 March 2006). Claims have now been amended to recited a method of screening for compounds that cause less loss of bone mineral density than a glucocorticoid; some of the claims are also drawn to in vivo screening methods.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. The claims, as amended, do not read on elected invention and thus will not be considered.

Since the above-mentioned amendment appears to be a bona fide attempt to reply, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD UNDER 37 CFR 1.136(a) ARE AVAILABLE.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shulamith H. Shafer, Ph.D. whose telephone number is 571-272-3332. The examiner can normally be reached on Monday through Friday, 8 AM to 5 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao, Ph.D. can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

> **LORRAINE SPECTOR PRIMARY EXAMINER**